Composition for ameliorating, preventing or treating 2019 coronavirus infection comprising bifidobacterium bifidum BGN4 as active ingredient

By activating T cell immunity with Bifidobacterium bifidobacterium BGN4 strain, the problem of limited effectiveness of existing vaccines and therapeutic agents has been solved, significantly reducing the symptoms and virus volume of COVID-19, demonstrating its ability to improve, prevent or treat Significant effect.

CN118902105APending Publication Date: 2024-11-08BIFIDO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410278890.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-08
Filing Date
2024-03-12
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing 2019 coronavirus vaccines and therapeutic agents have limited effects and lack of animal models that truthfully demonstrate human 2019 coronavirus, making it difficult to develop the best vaccines and therapeutic agents, especially the role of T-cell immune responses in prevention and treatment. More importantly, but existing vaccines mainly rely on B-cell immunity.

Method used

Bifidobacterium bifidum BGN4 strain was used as an active ingredient to activate the T cell immune response and serve as a food or drug ingredient to improve, prevent or treat 2019 coronavirus infection, and experimentally verified its effect using animal models.

Benefits of technology

Bifidobacterium bifidobacterium BGN4 strain significantly reduced body temperature fluctuations and weight loss caused by COVID-19 infection, increased the content of the anti-inflammatory cytokine IL-10, reduced lung inflammation and virus volume, demonstrating that it is improving, preventing or It has excellent results in treating 2019 coronavirus infection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118902105A_ABST
    Figure CN118902105A_ABST
Patent Text Reader

Abstract

The present invention relates to a composition for ameliorating, preventing or treating 2019 coronavirus infection, which comprises, as an active ingredient, a Bifidobacterium bifidum BGN4 (KCCM12754P) strain, and to a method for improving, preventing or treating 2019 coronavirus infection, said composition comprising, as an active ingredient, a Bifidobacterium bifidum BGN4 strain. The composition according to the present invention, which contains a Bifidobacterium bifidum BGN4 (KCCM12754P) strain as an active ingredient, can exhibit an effect of improving, preventing, or treating infection with a 2019 coronavirus (covid-19).
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a composition for improving, preventing or treating 2019 coronavirus (covid-19) infection, comprising Bifidobacterium bifidum BGN4 (KCCM12754P) as an effective ingredient. Background Art

[0002] The coronavirus, which was first discovered 60 years ago, appeared in 2003 as SARS-CoV, which caused a deadly respiratory infection in humans, and then a new mutant pathogen called SARS-CoV-2 appeared in 2019, which is currently causing the very serious COVID-19 global pandemic. After the vaccine against COVID-19 infection was developed in 2021, although countries around the world completed the injection of booster shots of COVID-19 vaccines, COVID-19 has not subsided, but has formed new mutations and is continuing to infect humans.

[0003] There are many reasons why COVID-19 infection has not subsided. The biggest reason is that the vaccines or therapeutics developed so far are not the best COVID-19 vaccines and therapeutics. Another big reason is that there is no animal model that faithfully represents COVID-19 in humans. The prominent features of COVID-19 infection in humans are respiratory symptoms, right hemiplegia where the inflammation of the right lung is more severe than that of the left lung, fever, chills, and secondary infection that metastasizes to the brain or liver. However, the COVID-19 animal models developed in the past only have respiratory symptoms and pneumonia, so it is basically difficult to regard them as COVID-19 infection models for humans. For this reason, it is difficult to develop the best COVID-19 vaccine and therapeutics through the COVID-19 infection animal studies developed in the past. Therefore, it is necessary to develop vaccines and therapeutics using animal models that faithfully represent COVID-19 in humans.

[0004] Thanks to the efforts made by the world in recent years to overcome the COVID-19 infection, various COVID-19 prevention vaccines such as mRNA vaccines, inactivated vaccines, recombinant vaccines, and live vaccines have been developed so far. These COVID-19 prevention vaccines prevent COVID-19 infection by stimulating B cells to form neutralizing antibodies against SARS-CoV-2. However, since the COVID-19 pandemic, although countries around the world have vaccinated against COVID-19 infection at least 2 times and up to 4 times, COVID-19 infection has not subsided at all. On the contrary, the number of confirmed COVID-19 patients has exploded as of July 2022, and it has become clear that the effectiveness of the COVID-19 prevention vaccines developed so far is limited.

[0005] It has recently been found that T cell immunity in the body plays a more important role than B cell immunity in eliminating the SARS-CoV-2 virus. Considering that neutralizing antibodies are formed through the B cell immune process, recent research results that indicate that T cell immune response is more important than B cell immunity in preventing / treating COVID-19 infection well explain why the COVID-19 preventive vaccine is not as effective as expected. Therefore, developing a method that can promote T cell immune response against SARS-CoV-2 will make great progress in preventing COVID-19 infection. The gut microbiome performs the function of enabling the T cell immune system to better recognize and eliminate pathogens by training T cell immune response. Therefore, the strains that make up the gut microbiome, especially probiotic strains, can be considered to have a very high probability of showing efficacy in improving, preventing or treating COVID-19 infection by activating T cell immune response to eliminate the SARS-CoV-2 virus that invades the body.

[0006] Prior art literature

[0007] Patent Literature

[0008] Patent document 1: Korean Patent Publication No. 10-2023-0040961 (publication date: 2023.03.23) relates to a composition for preventing or treating coronavirus infection containing tetrandrine or its analogs, and records the effects of fangjinoline and cephalaenopsis as tetrandrine or its analogs in inhibiting infection with coronaviruses such as MERS-coronavirus, SARS-coronavirus, SARS-coronavirus-2 and human-coronavirus. Summary of the invention

[0009] The present invention aims to provide a composition comprising Bifidobacterium bifidum BGN4 (KCCM12754P), which has the effect of improving, preventing or treating 2019 coronavirus infection.

[0010] The present invention provides a food composition for improving 2019 coronavirus infection, which comprises Bifidobacterium bifidum BGN4 (KCCM12754P) strain as an effective ingredient.

[0011] In addition, the present invention provides a pharmaceutical composition for preventing or treating 2019 coronavirus infection, which comprises Bifidobacterium bifidum BGN4 (KCCM12754P) strain as an active ingredient.

[0012] Furthermore, the present invention provides an animal food composition for improving 2019 coronavirus infection, which comprises Bifidobacterium bifidum BGN4 (KCCM12754P) strain as an active ingredient.

[0013] In addition, the present invention provides an animal medicine for preventing or treating 2019 coronavirus infection, which comprises Bifidobacterium bifidum BGN4 (KCCM12754P) strain as an active ingredient.

[0014] The composition of the present invention comprising Bifidobacterium bifidum BGN4 (KCCM12754P) as an active ingredient can improve, prevent or treat 2019 coronavirus infection. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 A graph showing the effect of oral administration of Bifidobacterium bifidum BGN4 on changes in body temperature in SH101 hamsters (G1: healthy control group (sample and virus non-administration group, n=5); G2: infection control group (SARS-CoV-2 virus infection group, n=10); G3-BGN4 (oral administration of BGN4 and SARS-CoV-2 virus infection group, n=10)).

[0016] Figure 2A graph showing the effect of oral administration of Bifidobacterium bifidum BGN4 on body weight changes in SH101 hamsters (G1-healthy control group (sample and virus unadministered group, n=5); G2-infected control group (SARS-CoV-2 virus infected group, n=10); G3-BGN4 (oral administration of BGN4 and SARS-CoV-2 virus infected group, n=10)).

[0017] Figure 3 The results are graphs showing the effect of administration of Bifidobacterium bifidum BGN4 on changes in body temperature in SH101 hamsters infected with SARS-CoV-2 (G1-healthy control group (sample and virus non-administration group, n=5); G2-infected control group (SARS-CoV-2 virus infection group, 1-12 days n=10, 13-14 days n=9, 15-21 days n=5); G3-BGN4 (oral administration of BGN4 and SARS-CoV-2 virus infection group, 1-11 days n=10, 12 days n=9, 13-14 days n=8, 15-21 days n=5), the statistical significance compared with the healthy control group is indicated in the graph as *p<0.05, **p<0.01, ***p<0.001).

[0018] Figure 4 Infrared thermographic representative images of each experimental group used to measure body temperature are shown (G1-healthy control group (group without sample and virus administration); G2-infected control group (group infected with SARS-CoV-2 virus); G3-BGN4 (group orally administered BGN4 and infected with SARS-CoV-2 virus)).

[0019] Figure 5 Graphs showing the effects of administration of Bifidobacterium bifidum BGN4 on weight changes in SH101 hamsters infected with SARS-CoV-2 (G1-healthy control group (sample and virus non-administration group, n=5); G2-infected control group (SARS-CoV-2 virus infection group, 1-12 days n=10, 13-14 days n=6, 15-21 days n=5); G3-BGN4 (oral administration of BGN4 and SARS-CoV-2 virus infection group, 1-11 days n=10, 12 days n=9, 13-14 days n=8, 15-21 days n=5), statistical significance compared to the healthy control group is indicated in the graph as *p<0.05, **p<0.01, ***p<0.001).

[0020] Figure 6 Graph showing the results of the distribution of the anti-inflammatory cytokine IL-10 in SH101 hamsters infected with SARS-CoV-2 (G1-healthy control group (sample and virus non-administered group, n=5); G2-infected control group (SARS-CoV-2 virus infected group, 4dpi n=4, 6dpi n=1, which were combined and expressed as 6dpi results, 14dpi n=5); G3-BGN4 (oral administration of BGN4 and SARS-CoV-2 virus infected group, 6dpi n=3, 14dpi n=5). The statistical significance compared with the infected control group is expressed in the graph as *p<0.05, **p<0.01, ***p<0.001).

[0021] Figure 7 Lung images of SH101 hamsters are shown (G1-healthy control group (group not administered with sample and virus); G2-infected control group (group infected with SARS-CoV-2 virus); G3-BGN4 (group orally administered with BGN4 and infected with SARS-CoV-2 virus)).

[0022] Figure 8 H&E-stained lung tissue images of SH101 hamsters are shown (G1-healthy control group (group not administered with sample and virus); G2-infected control group (group infected with SARS-CoV-2 virus); G3-BGN4 (group orally administered with BGN4 and infected with SARS-CoV-2 virus). The scale bar represents 100 μm at 100x and 25 μm at 400x).

[0023] Fig. 9 It is a curve chart of the results of virus quantitative analysis of SH101 hamsters infected with SARS-CoV-2 (G1-healthy control group (sample and virus non-administered group, n=5); G2-infected control group (SARS-CoV-2 virus infected group, 4dpi n=4, 6dpin=1, which were combined and expressed as 6dpi results, 14dpi n=5); G3-BGN4 (oral administration of BGN4 and SARS-CoV-2 virus infected group, 6dpi n=3, 14dpi n=5). The statistical significance compared with the infected control group is expressed in the curve chart as *p<0.05, **p<0.01, ***p<0.001). DETAILED DESCRIPTION

[0024] After the first discovery of coronavirus 60 years ago, a new variant pathogen called SARS-CoV-2 appeared in 2019 and caused a very serious global pandemic of COVID-19. Since existing vaccines or therapeutics have limitations in treating this virus, it is necessary to develop effective vaccines and therapeutics by using animal models that faithfully represent COVID-19 in humans. In addition, in order to treat COVID-19, it is important to promote T cell immunity, and it is required to effectively improve, prevent or treat COVID-19 infection by activating T cell immunity to eliminate SARS-CoV-2 that has invaded the body.

[0025] Therefore, the present invention provides a food composition for improving 2019 coronavirus infection, which comprises Bifidobacterium bifidum BGN4 (KCCM12754P) strain as an effective ingredient. In addition, the present invention provides a pharmaceutical composition for preventing or treating 2019 coronavirus infection, which comprises Bifidobacterium bifidum BGN4 (KCCM12754P) strain as an effective ingredient.

[0026] Furthermore, an animal food composition for improving COVID-19 infection is provided, which comprises the BGN4 (KCCM12754P) strain of Bifidobacterium bifidum as an effective ingredient. Furthermore, the present invention provides an animal medicine for preventing or treating COVID-19 infection, which comprises the BGN4 (KCCM12754P) strain of Bifidobacterium bifidum as an effective ingredient.

[0027] The Bifidobacterium bifidum BGN4 (KCCM12754P) strain used in the present invention is a strain deposited in the Korea Collection of Microorganisms (foreign) on June 24, 2020, with a deposit number of KCCM12754P. It is a strain disclosed by Korean Patent No. 10-2314736 (authorized on October 13, 2021) and the like.

[0028] When infected with COVID-19 and the symptoms caused by it become severe, it is difficult to maintain normal weight and body temperature, and this can lead to rapid weight loss or hypothermia after a high fever. Therefore, whether the therapeutic material has a beneficial effect can be confirmed by clinical observation of changes in weight and body temperature in response to COVID-19 infection.

[0029] In addition, reducing the inflammation produced during viral infection is crucial to improving, preventing or treating the 2019 coronavirus. Especially because the 2019 coronavirus has a fatal impact on the lungs, effectively reducing the degree of inflammation or the amount of virus detected in the lungs is a very important factor.

[0030] Therefore, in the present invention, by using animal models to conduct multiple experiments related to the 2019 coronavirus, it can be seen that the Bifidobacterium bifidum BGN4 (KCCM12754P) strain of the present invention keeps the body weight constant without signs of hypothermia, and thus has excellent effects in improving, preventing or treating 2019 coronavirus infection. In addition, the strain of the present invention also effectively improves immune function by increasing the content of interleukin-10 (IL-10), which is an anti-inflammatory cytokine, and the inflammation of the lungs is significantly reduced and the amount of SARS-CoV-2 detected in the lungs is reduced, so it can be seen that it has excellent effects on improving, preventing or treating 2019 coronavirus infection caused by SARS-CoV-2.

[0031] As such, the present invention provides the Bifidobacterium bifidum BGN4 (KCCM12754P) strain and a composition containing it as an active ingredient to confirm the possibility of using it as a strain that is effective in improving, preventing or treating 2019 coronavirus infection. This is particularly significant because it is confirmed by using an animal model that particularly faithfully represents human 2019 coronavirus infection, and its role as an intestinal microorganism to effectively eliminate pathogens by activating T cell immunity is confirmed.

[0032] On the other hand, in the present invention, the above-mentioned food composition or animal food composition examples can be any one selected from meat, cereals, caffeinated beverages, ordinary beverages, chocolate, bread, snacks, biscuits, pizza, soft candy, noodles, chewing gum, ice cream, alcoholic beverages, wine, multivitamins and other health supplements, but are not limited to these.

[0033] Furthermore, in the food composition or animal food composition of the present invention, the amount of the Bifidobacterium bifidum BGN4 (KCCM12754P) strain is not limited and can be varied according to the state of the subject, the type of specific symptoms, the degree of development, etc. If necessary, it can also be included as the total content of the food. In the present invention, preferably, when the hamster model is used as the subject, 5×10 9 CFU / 100μL.

[0034] Also, when the food composition or animal food composition of the present invention is used in the form of a food additive, it may be directly added or used together with other foods or food ingredients, and may be appropriately used according to conventional methods.

[0035] On the other hand, the pharmaceutical composition of the present invention or animal medicine can also include pharmaceutically acceptable carriers, diluents or excipients. Available carriers, excipients or diluents include lactose, glucose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum arabic, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talcum powder, magnesium stearate and mineral oil, and can use one or more selected from them. And, when therapeutic agent and preventive agent are medicaments, fillers, anticoagulants, lubricants, wetting agents, spices, emulsifiers or preservatives etc. can be further included.

[0036] On the other hand, the dosage form of the pharmaceutical composition or animal drug of the present invention can be prepared into the best form according to the method of use, in particular, it is preferably prepared by adopting methods known in the art so that the active ingredient is provided for rapid, sustained or delayed release after administration to a mammal. Specific examples of dosage forms can be selected from plasters, granules, lotions, liniments, lemonades, aromatic waters, powders, syrups, ophthalmic ointments, liquids and solutions, aerosols, extracts, elixirs, ointments, fluid extracts, emulsions, suspensions, decoctions, infusions, eye drops, and ointments. Any of solutions, tablets, suppositories, injections, spirits, potions, capsules, creams, troches, tinctures, pastes, pills, soft or hard gelatin capsules.

[0037] On the other hand, in the pharmaceutical composition or animal drug of the present invention, the dosage is preferably determined in consideration of the method of administration, the age, sex, weight of the user, and the severity of the disease. However, the dosage effective for the desired treatment can be easily changed according to the user's condition and the doctor's prescription. In addition, the pharmaceutical composition or animal drug of the present invention can be administered once a day or divided into several doses per week or month.

[0038] Furthermore, the pharmaceutical composition or animal drug of the present invention can be administered as a single therapeutic agent or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with existing therapeutic agents. Taking all the above factors into consideration, the amount of administration that can achieve the maximum effect without side effects can be administered in the minimum amount, and this can be easily determined by a person of ordinary skill in the art.

[0039] Hereinafter, the present invention will be described in more detail by the following embodiments or experimental examples. However, the scope of the invention claimed in the present invention is not limited to the following embodiments or experimental examples, but also includes modifications of the technical ideas equivalent thereto.

[0040] Example 1: Evaluation of the anti-2019 coronavirus efficacy of Bifidobacterium bifidum BGN4 (KCCM12754P) through animal experiments

[0041] 1) Preparation of animal models

[0042] The experiment of accurately evaluating whether Bifidobacterium bifidum BGN4 (KCCM12754P) has the effect of treating 2019 coronavirus infection will be carried out by animal model, and inbred hamsters are used to carry out the experiment so that they have the same genetic background. For this reason, SH101 hamsters (Chongkai et al., 2021, "Roborovski hamster (Phodopusroborovskii) strain SH101 as a systemic infection model of SARS-CoV-2. Virulence". Dec; 12 (1): 2430-2442. doi: 10.1080 / 21505594.2021.1972201.) known as the most accurate expression of human 2019 coronavirus infection symptoms are used. SH101 hamsters aged 3 months raised in the animal breeding facility of Chonbuk National University College of Medicine were divided into male and female hamsters and placed in small animal cages in the ABL3 animal breeding room of the Institute of Zoonotic Infectious Diseases of Chonbuk National University, with less than 5 hamsters in each cage. Each hamster was allowed to freely consume D12450B (fat intake, 10% kcal; Research Diets Inc.) feed and drinking water. After adapting for about 7 days and observing the general health status, healthy individuals were selected for the experiment. The laboratory environment had a temperature of 22℃±1℃, a humidity of 55%±5%, and a 12-hour light and dark cycle (lights on time: 8:30). By adding 50μL of SARS-CoV-2 aqueous solution (10 5 TCID 50 ) was directly injected into the nasal cavity of SH101 hamsters to prepare the 2019 coronavirus infection animal model. The strain dosage and conditions of each experimental group are shown in Table 1 below.

[0043] Table 1

[0044]

[0045] The healthy control group was injected with the same amount of Dulbecco's modified Eagle's medium (DMEM, Gibco, USA) instead of the SARS-CoV-2 aqueous solution into the nasal cavity of the hamsters, and 100 μL of saline was orally administered to the hamsters. The infected control group was injected with 50 μL of the SARS-CoV-2 aqueous solution (10 5 TCID 50) was directly injected into the nasal cavity of SH101 hamsters to induce 2019 coronavirus infection, and then 100 μL of physiological saline was orally administered to the hamsters. The sample administration group for evaluating the Bifidobacterium bifidum BGN4 strain was pre-colonized in the intestine (see "2) Intestinal microbial analysis" below), and then 50 μL of SARS-CoV-2 aqueous solution (10 5 TCID 50 ) was directly injected into the nasal cavity of hamsters to induce 2019 coronavirus infection. In each experimental group, freeze-dried strains were injected at 5×10 9 The amount of CFU / hamster was diluted in physiological saline and orally administered. Then, the prepared hamsters were used for experimental evaluation.

[0046] The SARS-CoV-2 strain used for 2019 coronavirus infection was obtained from the National Culture Collection for Pathogens (NCCP) of the Korea Disease Control and Prevention Agency (KDCA). The complete genome information of SARS-CoV-2 strain is included in GISAID (identifier: BetaCoV / Wuhan / IVDC-HB-01 / 2020|EPI_ISL_402119) and is also registered in the Chinese Microbiological Data Center (accession number NMDC10013001 and genome accession number MDC60013002-01). SARS-CoV-2 strain was cultured on Verocell at 37°C and 5% CO2 in Dulbecco's modified Eagle's medium (DMEM, Gibco, USA), and the virus infected with Verocell was isolated and used in the experiment. The tissue culture infectious dose endpoint (tissue culture infectious dose endpoint) was used as the endpoint dilution assay. dosednpoint)(TCID 50 ) to determine the amount of SARS-CoV-2 virus. The virus culture was serially diluted 10-fold to 10 -1 ~10 -11Each dilution was then inoculated into the same wells of a 96-well microplate (Falcon, Lincoln, NJ, USA) and cultured. The cells lysed by the virus were visualized, and the dilution of the wells showing more than 50% cytopathic effect (CPE) was calculated using the Reed-Muench method, and the virus titer was expressed as TCID 50 / mL.

[0047] The sample for evaluating the effectiveness of Bifidobacterium bifidum BGN4 was prepared based on the weight of 20 g of hamsters and diluted with physiological saline. The viable cell count of the lyophilized product of Bifidobacterium bifidum BGN4 was 5.27×10 11 CFU / g, and diluted with saline to a final concentration of 5×10 9 CFU / 100 μL, and then orally administered to hamsters. The evaluations performed below were approved by the Institutional Animal Care and Use Committee (IACUC) of Chonbuk National University (approval number: JBNU 2021-0184) and performed in accordance with the committee's regulations and procedures to review the ethics, scientific validity, and effective management of experimental animals.

[0048] 2) Intestinal microbial analysis

[0049] PCR and electrophoresis were performed to confirm the presence of Bifidobacterium bifidum BGN4 strain in the intestines of hamsters. To extract DNA from feces, hamsters were grouped into small animal cages and feces were collected, and then 25 mg of the collected feces and 800 μL of lysis buffer (0.5 M NaCl, 50 mM Tris-HCl, pH 8.0, 50 mM EDTA, 4% sodium dodecyl sulfate) were added to a 2 mL round-bottom tube containing 0.5 cm stainless steel beads, and cells were lysed (Cell lysis) at 13000 rpm for 1 minute using Automill (Tokken, Inc., TK-AM7, Japan). 700 μL of the cell lysate was transferred to a 1.5 mL micro-tube, 700 μL of Phenol-Chloroform Isoamyl Alcohol solution was added, mixed thoroughly and centrifuged at 14000×g, 4°C for 5 minutes. 600 μL of the separated supernatant was transferred to a 1.5 mL micro-tube, 600 μL of chloroform was added, mixed thoroughly and centrifuged at 14000×g, 4°C for 5 minutes. 500 μL of the separated supernatant was transferred to a 1.5 mL micro-tube, 50 μL of 3M sodium acetate was added, mixed thoroughly and reacted in an ice bottle for 5 minutes. 600 μL of cold isopropanol was added here and reacted in an ice bottle for 10 minutes, and then centrifuged at 14000×g, 4°C for 15 minutes to separate the supernatant. After separating the supernatant, 500 μL of 70% cold ethanol was added to the DNA pellet, which was washed and dried, and then 50 μL of TE buffer (10 mM Tris, 1 mM EDTA, pH 8.0) was added to mix and stored at -20°C. TMPCR was performed using EF-Taq NDA polymerase (Solgent Co., Korea). The primers used for PCR were provided by Bifid Co., Ltd. The primer information for confirming Bifidobacterium bifidum BGN4 was as follows: Primer F (5'-GCAAGCGAATTCTGTGAACGGTT-3'), Primer R (5'-CAGCTGATAGGCCGTAGAGTTCAC-3'), and the PCR reaction conditions were shown in Table 2.

[0050] Table 2

[0051]

[0052] A 1.2% agarose gel was prepared using TAE buffer (40mM Tris-aceta, 1mM EDTA) to perform electrophoresis on the PCR reactants. The PCR reactants were mixed with 5μL of loading dye (0.25% bromphenol blue, 0.25% xylene cyanol, 30% glycerol) and loaded onto the gel. The band size was confirmed using a DNA size marker to confirm whether the strains in the test group were colonized in the hamster intestine. When the BGN4 strain of Bifidobacterium bifidum in the hamster intestine was present as a constituent strain of the intestinal microbiome, the evaluation results could not be accurately determined. In order to solve this problem, fresh feces from each SH101 hamster was first received, and then the DNA amplified with specific primers for each strain was electrophoresed to confirm the bands. Hamsters with no Bifidobacterium bifidum BGN4 strain in their intestinal microbiota were screened by this method and used in this evaluation experiment.

[0053] 3) Clinical observation

[0054] 3-1) Observe weight changes and ask questions

[0055] The changes in body temperature of hamsters due to SARS-CoV-2 virus infection and drug administration were measured using a thermal imager. Thermal images of the entire body of the hamsters were taken using a thermal imager (FLIR, USA) during the experiment, and the thermal images were analyzed according to body temperature using the DirA program (FLIRTools). The body temperature of the hamsters was expressed by measuring the most superficial temperature of the chest close to the lungs, and the highest temperature point in the thermal image was selected for measurement. All data are expressed as mean ± standard deviation, and the differences between groups were compared and analyzed using Student's t-test at the p<0.05 level.

[0056] On the other hand, a weighing scale was used to measure the weight changes of hamsters due to SARS-CoV-2 virus infection and drug administration. The weight of the hamsters was measured during the experiment, and the weight change rate (%) was expressed by [current weight / 0dpi weight × 100]. All data were expressed as mean ± standard deviation, and the differences between the groups were compared and analyzed at the p < 0.05 level using Student's t-test.

[0057] Each hamster group consisted of 10 hamsters. The strain was administered to each hamster group for 7 days and the body weight and body temperature were observed every day. Figure 1 as well as Figure 2 As shown, the body weight and body temperature of the experimental group to which the Bifidobacterium bifidum BGN4 strain was continuously administered for 7 days were not significantly different from those of the normal control group. Thus, it was confirmed that the administration of the Bifidobacterium bifidum BGN4 strain had no adverse effect on the health of the hamsters and maintained a normal state.

[0058] 3-2) Observe the changes in body weight and body temperature after SARS-CoV-2 infection

[0059] The temperature changes were observed as described above by measuring the chest surface temperature as close to the lungs as possible, and the highest temperature point in the thermal image was selected for measurement. The temperature changes were measured for 21 days (on the 8th day of infection with SARS-CoV-2 virus). Each data is expressed as mean ± standard deviation, and the results are shown as follows Figure 3 as well as Figure 4As shown. Similar to the infection control group, the Bifidobacterium bifidum BGN4 strain administration group developed a high fever immediately after infection with SARS-CoV-2 at 1dpi. The infection control group developed hypothermia as a phenomenon that occurred as the symptoms of the 2019 coronavirus worsened at 3dpi, but hypothermia did not occur in the Bifidobacterium bifidum BGN4 strain administration group, and it was observed that the body temperature gradually returned to normal from 4dpi. The hypothermia phenomenon after high fever is a typical sign of disease development of severe 2019 coronavirus infection, and is a typical symptom observed in humans or animal models with severe 2019 coronavirus infection. Unlike severe illness, mild illness is characterized by no hypothermia after high fever and returning to normal as the body temperature returns to normal. Based on this body temperature characteristic, it can be evaluated that Bifidobacterium bifidum BGN4 prevents SARS-CoV-2 infection from progressing to severe 2019 coronavirus infection.

[0060] The efficacy of Bifidobacterium bifidum BGN4 strain in preventing COVID-19 infection was determined by measuring the weight loss associated with COVID-19 infection. The weight change was measured for 21 days (day 8 of infection with SARS-CoV-2 virus). Each data is expressed as mean ± SD. The results are shown in Table 1. Figure 5 As shown, the infected control group lost up to 12±8% compared with the initial body weight at 4dpi, and the Bifidobacterium bifidum BGN4 administration group was 98±4% to 105±3%, showing relatively little change. Weight loss is one of the most significant characteristics of patients with severe 2019 coronavirus infection. Based on this characteristic, hamsters administered with Bifidobacterium bifidum BGN4 strain maintained normal weight throughout the experiment, thus indicating that Bifidobacterium bifidum BGN4 strain effectively prevents 2019 coronavirus infection.

[0061] 4) Blood analysis

[0062] Blood analysis was performed as follows. First, whole blood was obtained from SH101 hamsters belonging to each group at 6 dpi and 14 dpi by cardiac puncture. The obtained whole blood was centrifuged at 2500×g for 10 minutes. Only part of the serum in the separated supernatant was carefully recovered, and the recovered serum was immediately frozen and stored at a temperature of -80°C and used for analysis.

[0063] 4-1) Analysis of inflammatory factors in blood

[0064] The level of cytokines associated with inflammation in the blood is an important indicator of the degree of inflammation produced in the body when pathogens invade the body and cause infection. IL-10 as an anti-inflammatory cytokine in hamster serum was quantitatively analyzed by quantitative ELISA method using Hamster interleukin-10 (IL-10, interleukin-10) ELISA Kit (MyBioSource, Cat. No. MBS8819724). Serum samples for analyzing inflammatory factors in the blood were prepared by diluting 10 times with sample dilution buffer. Standard solutions were also prepared by serial dilution with sample dilution buffer. The 10-fold diluted sample was dropped into a micro-ELISA plate coated with a capture antibody for IL-10 at 100 μL per well, and then reacted at 37°C for 90 minutes before adding a biotin-labeled antibody solution for reaction, followed by washing with a wash buffer. Next, HRP-streptavidin conjugate was added for post-reaction washing. Finally, the chromogenic substrate was added and reacted according to the instructions, and then the reaction stop solution was added to stop the reaction. After the reaction was terminated, the OD value was immediately measured at 450 nm using an ELISA reader (iMark microplate reader, Bio Rad, Cat No.#1681130). In this case, the average OD450 is obtained from at least 2 or more measured values, and the blank OD450 is subtracted therefrom for correction, thereby obtaining the final average OD450 value of each sample. Standard samples with concentrations of 6.25pg / ml, 12.5pg / ml, 25pg / ml, 50pg / ml, 100pg / ml, 200pg / ml, and 400pg / ml are used to obtain a standard curve for IL-10 quantitative analysis. Each concentration is calculated using the standard curve by the OD450 value obtained from each sample. All data are expressed as mean ± standard deviation, and the significant differences between the groups are compared and analyzed at the p<0.05 level using a one-way ANOVA multiple comparison's test.

[0065] Results, such as Figure 6 As shown, the content of anti-inflammatory cytokine IL-10 in hamsters due to infection was 18±14.2% (6dpi) and 24±1.8% (14dpi), which was not much different from the healthy control group, but compared with the infected control group, the Bifidobacterium bifidum BGN4 administration group increased by 92±4.5% (6dpi, p<0.001) and 52±17.9% (14dpi, p<0.001). In summary, it shows that oral administration of Bifidobacterium bifidum BGN4 strain helps regulate the immune activity in SH101 hamsters.

[0066] 5) Biopsy

[0067] After completing the clinical and serological analysis for each administration group, the lungs removed at 6dpi and 14dpi were subjected to histological observation. First, 5 SH101 hamsters belonging to the infection control group and the sample administration group were euthanized at 6dpi and 14dpi, and the lungs were separated by laparotomy. After photographing the entire isolated lung with a digital camera, the right lobe of the lung was immediately fixed with 10% neutral formalin to stain the lung tissue by the H&E method. After washing the fixed tissue according to the tissue processing process, it was dehydrated with ethanol. Then, it was made transparent with xylene and embedded in paraffin through a paraffin infiltration process. The embedded tissue was cut into slices with a thickness of 5μm and attached to a glass slide, and H&E staining was performed after deparaffinization and dehydration. Changes in lung tissue such as infiltration of inflammatory cells and fibrosis were observed under an optical microscope. For H&E staining, the cell nuclei on the slide were stained with Harris hematoxylin solution for 5 minutes, then washed, soaked in 1% HCl-alcohol solution 3 times, and then washed thoroughly with running water. After staining blue with 1% ammonia solution, the cytoplasm was stained with eosin solution for 3 minutes, and then dehydrated by soaking in 80% ethanol 3 times, 95% ethanol 3 times, and 100% ethanol 3 times. The stained tissue was sealed with a sealing agent and a cover glass.

[0068] Results, such as Figure 7As shown, it can be confirmed that red spots caused by inflammation were found in the lungs of the SARS-CoV-2 infection control group, and the size or number of the spots increased according to the degree of infection. And it can be seen that, in contrast, the lungs of the Bifidobacterium bifidum BGN4 administration group had mild inflammation, and the degree of inflammation in the lungs was more severe at 6 dpi than at 14 dpi. This result intuitively shows that the administration of Bifidobacterium bifidum BGN4 has the effect of preventing SARS-CoV-2, thereby reducing lung inflammation overall.

[0069] In addition, H&E staining was performed on the lungs isolated from each dosing group and the biopsy results were observed, as shown in FIG. Figure 8 As shown, a significant increase in inflammatory cells was confirmed in the lung tissue of the infection control group (indicated by black arrows), and it was confirmed that the inflammatory expression level of the lung tissue of the Bifidobacterium bifidum BGN4-administered group was weaker than that of the infection control group by H&E staining.

[0070] 6) Quantitative detection of viruses

[0071] SARS-CoV-2 virus quantitative analysis was performed by extracting mRNA from lung tissues of the infection control group and the sample administration group isolated from SH101 hamsters. First, SH101 hamsters belonging to the infection control group and the sample administration group were euthanized at 6dpi and 14dpi, and then the lung organs were separated by dissection. The separated part of the left lobe of the lung was homogenized with a tissue homogenizer and then centrifuged at 3000xrpm for 10 minutes at 4°C. Samples were prepared by extracting RNA from the supernatant obtained by centrifugation using the RNeasy Mini Kit (QIAGEN, Hilden, Germany) according to the guidelines. Then, RT-qPCR was performed using the PrimerScript RT Reagent Kit (TaKaRa, Japan). The primers used for RT-qPCR were the forward primer for the envelope protein (E) gene of the SARS-CoV-2 virus: 5'-GCCTCTTCTCGTTCCTCATCAC-3' and the reverse primer: 5'-AGCAGCATCACCGCCATTG-3'. The RT-qPCR reaction was performed using the iQ SYBR Green SuperMix Kit (BioRad, USA) under the following conditions: DNA denaturation: 3 minutes at 95°C for 3min; DNA amplification: 40 cycles of [15sec at 95°C, 30sec at 60°C]). The real-time fluorescence quantitative PCR standard curve was generated by serial dilution of the recombinant plasmid and used as a quantitative standard. The Ct value of each sample was used to quantify the virus titer using a standard curve. All data were expressed as mean ± standard deviation, and the significant differences between the groups were compared and analyzed at the p < 0.05 level using a one-way ANOVA multiple comparison test.

[0072] Results, such as Fig. 9 As shown, 3.35×10 5 ±5.57×10 4 / g, 4.03×10 2 ±6.32×101 / g of virus, and the amount of virus detected in the Bifidobacterium bifidum BGN4-administered group during the trial was significantly less than that in the infected control group. The amount of virus in the Bifidobacterium bifidum BGN4-administered group was 4.81×10 4 ±2.12×10 4 / g(6dpi,p<0.001),2.02×10 2 ±2.34×10 1 / g (14dpi, p<0.05), which was reduced by 86±10.3% (6dpi) and 50±9.9% (14dpi) compared with the infected control group. It was thus judged that the administration of Bifidobacterium bifidum BGN4 has the effect of preventing 2019 coronavirus infection.

Claims

1. A food composition for improving COVID-19 infection, characterized in that: The invention comprises the Bifidobacterium bifidum BGN4 strain with the deposit number of KCCM12754P as an effective ingredient.

2. A pharmaceutical composition for preventing or treating COVID-19 infection, characterized in that: The invention comprises the Bifidobacterium bifidum BGN4 strain with the deposit number of KCCM12754P as an effective ingredient.

3. An animal food composition for improving COVID-19 infection, characterized in that: The invention comprises the Bifidobacterium bifidum BGN4 strain with the deposit number of KCCM12754P as an effective ingredient.

4. An animal medicine for preventing or treating COVID-19 infection, characterized in that: The invention comprises the Bifidobacterium bifidum BGN4 strain with the deposit number of KCCM12754P as an effective ingredient.